Mankind Pharma reports strong sustainability performance for FY25

Mankind Pharma reported strong ESG performance for FY2024-25, with total turnover of ₹9,497.80 crore and net worth of ₹14,640.27 crore.

The company invested 100% of R&D spending in technologies to improve environmental and social impacts, while allocating 22% of capex to environmental performance improvements. Sustainable sourcing accounted for 25% of procurement value.

Energy consumption totaled 6,06,493 GJ, with 3,79,070 GJ from renewable sources - representing a significant shift toward clean energy.

All employees received human rights training, and the company provided 100% health and accident insurance coverage for permanent staff.